

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

76-553

MICROBIOLOGY REVIEW

Product Quality Microbiology Review

Review for HFD-620

June 20, 2003

ANDA: 76-553

Drug Product Name

Proprietary: N/A

**Non-proprietary: Medroxyprogesterone Acetate Injectable Suspension,
USP**

Drug Product Classification: Contraceptive

Review Number: #1

Subject of this Review

Submission Date: November 27, 2002

Receipt Date: November 29, 2002

Consult Date: N/A

Date Assigned for Review: June 16, 2003

Submission History (for amendments only)

Date(s) of Previous Submission(s): N/A

Date(s) of Previous Micro Review(s): N/A

Applicant/Sponsor

Name: Gensia Sicor Pharmaceuticals, Inc.

Address: 19 Hughes, Irvine, CA 92618-1902

Representative: Elvia O. Gustavson

Telephone: 949-455-4724

Name of Reviewer: Nrapendra Nath

Conclusion: The submission is **recommended** for approval on the basis of sterility assurance.

Product Quality Microbiology Data Sheet

- A.
1. **TYPE OF SUPPLEMENT:** N/A
 2. **SUPPLEMENT PROVIDES FOR:** N/A
 3. **MANUFACTURING SITE:**
Gensia Sicor Pharmaceuticals
19 Huges
Irvine, CA 92618
 4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** 150mg/mL as 1mL fill in 2mL Vial; I/M
 5. **METHOD(S) OF STERILIZATION:** _____
 6. **PHARMACOLOGICAL CATEGORY:** Contraceptive
- B. **SUPPORTING/RELATED DOCUMENTS:** ANDA 76-552
- C. **REMARKS:** The subject ANDA is similar to ANDA 40-454, which was reviewed by the subject reviewer in June 2002, in its sterility assurance content.
- The ANDA 76-552 is similar to the subject ANDA except that it is filled in glass syringes instead of glass vials.

**APPEARS THIS WAY
ON ORIGINAL**

Executive Summary

I. Recommendations

- A. Recommendation on Approvability -**
The submission is **recommended** for approval on the basis of sterility assurance. Specific comments are provided in the "Product Quality Microbiology Assessment" section.
- B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable – N/A**

II. Summary of Microbiology Assessments

- A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology -**
The subject drug product consists of a suspension and is manufactured _____ as single dose in glass vials.
- B. Brief Description of Microbiology Deficiencies -**
None.
- C. Assessment of Risk Due to Microbiology Deficiencies -**
None.

III. Administrative

- A. Reviewer's Signature** Nrapendra Nath 7/9/03
- B. Endorsement Block**
Microbiologist / Nrapendra Nath
Microbiology Team Leader/Neal J. Sweeney *Neal J. Sweeney*
7-10-03
- C. CC Block**
cc:
Original ANDA
HFD- 600
Division File
V:\MICROREV\76-553.doc

Redacted 16 page(s)

of trade secret and/or

confidential commercial

information from

MICROBIOLOGY REVIEW #1